17,261 trials
Intrahepatic Cholangiocarcinoma · Combined Hepatocellular and Cholangiocarcinoma
Primary: Substudy 1: Objective Response Rate (ORR) — 22.3 Percentage of participants
Heart Failure
Primary: Difference in Peak Oxygen Consumption (Vo2) Between KNO3 and KCl Phases — 10.31714; 10.215172 L/min/kg — p=0.6191
Heart Failure
Primary: The Percentage of Individuals in Each Group With a Significant Decline in the LVEF. — 22; 9 Participants
Paroxysmal Nocturnal Hemoglobinuria
Primary: Summary of Lactate Dehydrogenase (LDH) Responders — 6; 5; 7; 5 Participants
Cervical Intraepithelial Neoplasia
Primary: Number of Subjects With Complete Response With the Intention-to-treat (ITT) Analysis — 12; 20 Participants
Acute Myeloid Leukemia
Primary: Number of Patients Who Relapsed — 5; 2; 0; 1 Participants
Scleroderma, Systemic · Interstitial Lung Disease
Primary: Percent Predicted Forced Vital Capacity (FVC-%) — 2.24; 2.09 percent predicted — p=0.9326
Hyperlipidaemia
Primary: Percentage Change From Baseline on Serum LDL-C — -56.7; 5.6 percent change — p=<0.001
Pancreatic Cancer · Stereotactic Body Radiation Therapy
Primary: CTCAE Grade 3 or 4 Gastro-intestinal (GI) Toxicities or Death Within 90 Days From the Start of Therapy — 1; 0; 0; 0 Events
Psoriasis · Plaque Psoriasis
Primary: Plasma Concentration of ARQ-151 Cream 0.3% — 3.15; 1.68 ng/mL
Oral Lichen Planus · Mucous Membrane Pemphigoid · Pemphigus Vulgaris
Primary: Mean Change From Baseline in Oral Pain Scores on the Visual Analog Scale (VAS) at 4 Weeks — 6.3; 4.4 score on a scale
Heart Failure With Preserved Ejection Fraction
Primary: KCCQ-12 — 47; 39 units on a scale
Multiple Myeloma
Primary: Change in Diarrhea as Assessed Per CTCAE v5.0 — 0.00; 0.13; 0.00; 0.13 CTCAE grade
Metastatic Triple Negative Breast Cancer
Primary: Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients…
Recurrent Bladder Urothelial Carcinoma · Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
Primary: Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS) — 27 percentage of participants